

# HEPATITIS C VIRUS TREATMENT GUIDELINES (Part 1 of 2)

Treatment naive		Peg-IFN/ribavirin treatment experienced	
Without cirrhosis	With compensated cirrhosis	Without cirrhosis	With compensated cirrhosis
<b>GENOTYPE 1A</b>			
<b>Recommended</b>			
<ul style="list-style-type: none"> <li>• Zepatier for 12wks<sup>1</sup> <b>OR</b></li> <li>• Mavyret for 8wks <b>OR</b></li> <li>• Harvoni for 12wks<sup>2</sup> <b>OR</b></li> <li>• Eplusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Zepatier for 12wks<sup>1</sup> <b>OR</b></li> <li>• Mavyret for 12wks <b>OR</b></li> <li>• Harvoni for 12wks <b>OR</b></li> <li>• Eplusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Zepatier for 12wks<sup>1</sup> <b>OR</b></li> <li>• Mavyret for 8wks <b>OR</b></li> <li>• Harvoni for 12wks <b>OR</b></li> <li>• Eplusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Zepatier for 12wks<sup>1</sup> <b>OR</b></li> <li>• Eplusa for 12wks <b>OR</b></li> <li>• Mavyret for 12wks</li> </ul>
<b>Alternative</b>			
<ul style="list-style-type: none"> <li>• Viekira Pak Or Viekira XR + ribavirin for 12wks <b>OR</b></li> <li>• Olysio + Sovaldi for 12wks <b>OR</b></li> <li>• Daklinza + Sovaldi for 12wks <b>OR</b></li> <li>• Zepatier + ribavirin for 16wks<sup>3</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Zepatier + ribavirin for 16wks<sup>3</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Viekira Pak Or Viekira XR + ribavirin for 12wks <b>OR</b></li> <li>• Olysio + Sovaldi for 12wks <b>OR</b></li> <li>• Daklinza + Sovaldi for 12wks <b>OR</b></li> <li>• Zepatier + ribavirin for 16wks<sup>3</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Harvoni + ribavirin for 12wks <b>OR</b></li> <li>• Zepatier + ribavirin for 16wks<sup>3</sup></li> </ul>
<b>GENOTYPE 1B</b>			
<b>Recommended</b>			
<ul style="list-style-type: none"> <li>• Zepatier for 12wks <b>OR</b></li> <li>• Mavyret for 8wks <b>OR</b></li> <li>• Harvoni for 12wks<sup>2</sup> <b>OR</b></li> <li>• Eplusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Zepatier for 12wks <b>OR</b></li> <li>• Mavyret for 12wks <b>OR</b></li> <li>• Harvoni for 12wks <b>OR</b></li> <li>• Eplusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Zepatier for 12wks <b>OR</b></li> <li>• Mavyret for 8wks <b>OR</b></li> <li>• Harvoni for 12wks <b>OR</b></li> <li>• Eplusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Zepatier for 12wks <b>OR</b></li> <li>• Eplusa for 12wks <b>OR</b></li> <li>• Mavyret for 12wks</li> </ul>
<b>Alternative</b>			
<ul style="list-style-type: none"> <li>• Viekira Pak Or Viekira XR for 12wks <b>OR</b></li> <li>• Olysio + Sovaldi for 12wks <b>OR</b></li> <li>• Daklinza + Sovaldi for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Viekira Pak<sup>4</sup> Or Viekira XR<sup>4</sup> for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Viekira Pak Or Viekira XR for 12wks <b>OR</b></li> <li>• Olysio + Sovaldi for 12wks <b>OR</b></li> <li>• Daklinza + Sovaldi for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Harvoni + ribavirin for 12wks <b>OR</b></li> <li>• Viekira Pak<sup>4</sup> Or Viekira XR<sup>4</sup> for 12wks</li> </ul>
<b>GENOTYPE 2</b>			
<b>Recommended</b>			
<ul style="list-style-type: none"> <li>• Mavyret for 8wks <b>OR</b></li> <li>• Eplusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Eplusa for 12wks <b>OR</b></li> <li>• Mavyret for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Mavyret for 8wks <b>OR</b></li> <li>• Eplusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Eplusa for 12wks <b>OR</b></li> <li>• Mavyret for 12wks</li> </ul>
<b>Alternative</b>			
Daklinza + Sovaldi for 12wks	Daklinza + Sovaldi for 16–24wks	Daklinza + Sovaldi for 12wks	Daklinza + Sovaldi for 16–24wks
<b>GENOTYPE 3</b>			
<b>Recommended</b>			
<ul style="list-style-type: none"> <li>• Mavyret for 8wks <b>OR</b></li> <li>• Eplusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Mavyret for 12wks <b>OR</b></li> <li>• Eplusa for 12wks<sup>7</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Eplusa for 12wks<sup>7</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Zepatier + Sovaldi for 12wks <b>OR</b></li> <li>• Vosevi for 12wks</li> </ul>
<b>Alternative</b>			
<ul style="list-style-type: none"> <li>• Daklinza + Sovaldi for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Vosevi for 12wks<sup>7</sup> <b>OR</b></li> <li>• Daklinza + Sovaldi +/- ribavirin for 24wks<sup>7</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Daklinza + Sovaldi for 12wks<sup>7</sup> <b>OR</b></li> <li>• Mavyret for 16wks <b>OR</b></li> <li>• Vosevi for 12wks<sup>7</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Eplusa + ribavirin for 12wks <b>OR</b></li> <li>• Mavyret for 16wks</li> </ul>
<b>GENOTYPE 4</b>			
<b>Recommended</b>			
<ul style="list-style-type: none"> <li>• Mavyret for 8wks <b>OR</b></li> <li>• Eplusa for 12wks <b>OR</b></li> <li>• Zepatier for 12wks <b>OR</b></li> <li>• Harvoni for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Eplusa for 12wks <b>OR</b></li> <li>• Mavyret for 12wks <b>OR</b></li> <li>• Zepatier for 12wks <b>OR</b></li> <li>• Harvoni for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Eplusa for 12wks <b>OR</b></li> <li>• Mavyret for 8wks <b>OR</b></li> <li>• Zepatier for 12wks<sup>8</sup> <b>OR</b></li> <li>• Harvoni for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>• Eplusa for 12wks <b>OR</b></li> <li>• Zepatier for 12wks<sup>8</sup> <b>OR</b></li> <li>• Mavyret for 12wks</li> </ul>

(continued)

# HEPATITIS C VIRUS TREATMENT GUIDELINES (Part 2 of 2)

Treatment naive		Peg-IFN/ribavirin treatment experienced	
Without cirrhosis	With compensated cirrhosis	Without cirrhosis	With compensated cirrhosis
<b>GENOTYPE 4 (continued)</b>			
<b>Alternative</b>			
Technivie + ribavirin for 12wks	Technivie <sup>4</sup> + ribavirin for 12wks	<ul style="list-style-type: none"> <li>Technivie + ribavirin for 12wks <b>OR</b></li> <li>Zepatier + ribavirin for 16wks<sup>8</sup></li> </ul>	<ul style="list-style-type: none"> <li>Technivie<sup>4</sup> + ribavirin for 12wks <b>OR</b></li> <li>Zepatier + ribavirin for 16wks<sup>8</sup> <b>OR</b></li> <li>Harvoni + ribavirin for 12wks</li> </ul>
<b>GENOTYPE 5, 6</b>			
<b>Recommended</b>			
<ul style="list-style-type: none"> <li>Mavyret for 8wks <b>OR</b></li> <li>Eplclusa for 12wks <b>OR</b></li> <li>Harvoni for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>Mavyret for 12wks <b>OR</b></li> <li>Eplclusa for 12wks <b>OR</b></li> <li>Harvoni for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>Mavyret for 8wks <b>OR</b></li> <li>Harvoni for 12wks <b>OR</b></li> <li>Eplclusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>Mavyret for 12wks <b>OR</b></li> <li>Harvoni for 12wks <b>OR</b></li> <li>Eplclusa for 12wks</li> </ul>

## PHARMACOLOGICAL THERAPIES

Generic	Brand	Strength	Form	Dosage
daclatasvir	<b>Daklinza</b>	30mg, 60mg, 90mg	tabs	60mg once daily. Concomitant strong CYP3A inhibitors <sup>10</sup> , PIs, cobicistat-containing regimens (except with darunavir): 30mg once daily. Concomitant moderate CYP3A inducers: <sup>11</sup> 90mg once daily
elbasvir/grazoprevir	<b>Zepatier</b>	50mg/100mg	tabs	1 tab once daily
glecaprevir/pibrentasvir	<b>Mavyret</b>	100mg/40mg	tabs	3 tabs once daily with food
ledipasvir/sofosbuvir	<b>Harvoni</b>	90mg/400mg	tabs	1 tab once daily
ombitasvir/paritaprevir/ritonavir	<b>Technivie</b>	12.5mg/75mg/50mg	tabs	2 tabs once daily in AM with a meal
ombitasvir/paritaprevir/ritonavir and dasabuvir	<b>Viekira Pak</b>	12.5mg/75mg/50mg and 250mg	tabs	Take with a meal. 2 tabs ombitasvir/paritaprevir/ritonavir once daily (in AM) and 1 tab dasabuvir twice daily (AM & PM)
	<b>Viekira XR</b>	8.33mg/50mg/33.33mg/200mg	ext-rel tabs	3 tabs once daily with a meal
ribavirin	<b>Copegus</b>	200mg	tabs	Take with food. Weight-based dosing (<75kg: 1000mg/day; ≥75kg: 1200mg/day in 2 divided doses). See full labeling.
simeprevir	<b>Olysio</b>	150mg	caps	1 cap once daily with food
sofosbuvir	<b>Sovaldi</b>	400mg	tabs	1 tab once daily
sofosbuvir/velpatasvir	<b>Eplclusa</b>	400mg/100mg	tabs	1 tab once daily
sofosbuvir/velpatasvir/voxilaprevir	<b>Vosevi</b>	400mg/100mg/100mg	tabs	1 tab once daily with food

## NOTES

For recommended and alternative regimens for specific patient populations (eg, treatment-experienced patients previously treated with regimens other than PEG-IFN/ribavirin, decompensated cirrhosis, HIV/HCV co-infection, renal impairment, etc), refer to the full guideline or drug manufacturer's labeling.

- Patients with no baseline NS5A RASs for elbasvir detected. Includes G1a substitutions at amino acid positions 28, 30, 31, or 93.
- An 8-week duration is recommended for treatment-naïve patients without cirrhosis who are non-black, HIV uninfected, and whose HCV RNA level is <6 million IU/ml.
- Patients who have baseline NS5A RASs for elbasvir. Includes G1a substitutions at amino acid positions 28, 30, 31, or 93.
- Reference FDA warning regarding use of ombitasvir/paritaprevir/ritonavir +/- dasabuvir in patients with cirrhosis (risk of hepatic decompensation/hepatic failure).
- Patients in whom no Q80K substitution is detected.
- Alternative only for patients who are negative for the Q80K substitution by commercially available resistance assay. Other recommended or alternative regimens should be used for patients with genotype 1a compensated cirrhosis in whom the Q80K substitution is present.
- Baseline RAS testing for Y93H is recommended. Ribavirin should be included in regimen or consider Vosevi if present.
- 12 weeks is recommended for patients who experience virologic relapse after PEG-IFN/ribavirin therapy. Patients with prior on-treatment virologic failure (failure to suppress or breakthrough) while on PEG-IFN/ribavirin should be treated with 16 weeks and have weight-based ribavirin added.
- For patients ineligible for ribavirin.
- Strong inhibitors (eg, clarithromycin, itraconazole, ketoconazole, ritonavir, nefazodone).
- Strong inducers (eg, bosentan, dexamethasone, efavirenz, etravirine, modafinil, nafcilin, rifampentine, rifapentine, nevirapine).

## REFERENCES

AASLD-IDS. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. <http://www.hcvguidelines.org>. Accessed December 15, 2017.

(Rev. 1/2018)